Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myelodysplasias

Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients

Leukemia volume 26, pages 2474–2482 (2012)Cite this article

Subjects

Abstract

Inositide signaling pathways can have a role in the Myelodysplastic Syndromes (MDS) progression to acute myeloid leukemia. Erythropoietin (EPO) is currently used in low-risk MDS, where it successfully corrects anemia in 50–70% of patients. However, some MDS patients are refractory to this treatment and little is known about the exact molecular mechanisms underlying the effect of EPO in these subjects. Here, we investigated the role of inositide pathways in low-risk MDS treated with EPO, mainly focusing on the Akt/PI-PLC (Phosphoinositide-Phospholipase C) gamma1 axis, which is activated by the EPO receptor, and PI-PLCbeta1/Cyclin D3 signaling, as Cyclin D3 is associated with hematopoietic proliferation and differentiation. Interestingly, EPO responder patients showed a specific activation of both the Akt/PI-PLCgamma1 pathway and beta-Globin gene expression, while nonresponders displayed an increase in PI-PLCbeta1 signaling. Moreover, in normal CD34+ cells induced to erythroid differentiation, PI-PLCbeta1 overexpression abrogated both EPO-induced Akt phosphorylation and beta-Globin expression. Overall, these findings suggest that PI-PLCbeta1 can act as a negative regulator of erythroid differentiation and confirm the involvement of Akt/PI-PLCgamma1 pathway in EPO signaling, therefore contributing to the comprehension of the effect of EPO in low-risk MDS and possibly paving the way to the identification of MDS patients at higher risk of refractoriness to EPO treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Scott BL, Deeg HJ . Myelodysplastic syndromes. Annu Rev Med 2010; 61: 345–358.

    Article  CAS  PubMed  Google Scholar 

  2. Kelaidi C, Fenaux P . Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond. Expert Opin Biol Ther 2010; 10: 605–614.

    Article  CAS  PubMed  Google Scholar 

  3. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011; 25: 1064–1079.

    Article  CAS  PubMed  Google Scholar 

  4. Nyakern M, Tazzari PL, Finelli C, Bosi C, Follo MY, Grafone T et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006; 20: 230–238.

    Article  CAS  PubMed  Google Scholar 

  5. Follo MY, Mongiorgi S, Bosi C, Cappellini A, Finelli C, Chiarini F et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007; 67: 4287–4294.

    Article  CAS  PubMed  Google Scholar 

  6. Follo MY, Finelli C, Bosi C, Martinelli G, Mongiorgi S, Baccarani M et al. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 2008; 22: 198–200.

    Article  CAS  PubMed  Google Scholar 

  7. Ramazzotti G, Faenza I, Fiume R, Matteucci A, Piazzi M, Follo MY et al. The physiology and pathology of inositide signaling in the nucleus. J Cell Physiol 2011; 226: 14–20.

    Article  CAS  PubMed  Google Scholar 

  8. Faenza I, Matteucci A, Manzoli L, Billi AM, Aluigi M, Peruzzi D et al. A role for nuclear phospholipase Cbeta 1 in cell cycle control. J Biol Chem 2000; 275: 30520–30524.

    Article  CAS  PubMed  Google Scholar 

  9. Faenza I, Ramazzotti G, Bavelloni A, Fiume R, Gaboardi GC, Follo MY et al. Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. Endocrinology 2007; 148: 1108–1117.

    Article  CAS  PubMed  Google Scholar 

  10. Furukawa Y . Cell cycle control genes and hematopoietic cell differentiation. Leuk Lymphoma 2002; 43: 225–231.

    Article  CAS  PubMed  Google Scholar 

  11. Cooper AB, Sawai CM, Sicinska E, Powers SE, Sicinski P, Clark MR et al. A unique function for cyclin D3 in early B cell development. Nat Immunol 2006; 7: 489–497.

    Article  CAS  PubMed  Google Scholar 

  12. Follo MY, Faenza I, Fiume R, Ramazzotti G, McCubrey JA, Martelli AM et al. Revisiting nuclear phospholipase C signalling in MDS. Adv Biol Regul 2012; 52: 2–6.

    Article  CAS  PubMed  Google Scholar 

  13. Follo MY, Bosi C, Finelli C, Fiume R, Faenza I, Ramazzotti G et al. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. Int J Mol Med 2006; 18: 267–271.

    CAS  PubMed  Google Scholar 

  14. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 2009; 106: 16811–16816.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Follo MY, Finelli C, Clissa C, Mongiorgi S, Bosi C, Martinelli G et al. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J Clin Oncol 2009; 27: 782–790.

    Article  PubMed  Google Scholar 

  16. Elliott S . Erythropoiesis-stimulating agents. Cancer Treat Res 2011; 157: 55–74.

    Article  CAS  PubMed  Google Scholar 

  17. Cortelezzi A, Colombo G, Pellegrini C, Silvestris I, Moronetti Mazzeo L, Bosari S et al. Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders. Am J Hematol 2008; 83: 531–539.

    Article  CAS  PubMed  Google Scholar 

  18. Bejar R, Levine R, Ebert BL . Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 2011; 29: 504–515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Marzo F, Lavorgna A, Coluzzi G, Santucci E, Tarantino F, Rio T et al. Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 2008; 26: 183–187.

    Article  CAS  PubMed  Google Scholar 

  20. Wang Y, Wu J, Wang Z . Akt binds to and phosphorylates phospholipase C-gamma1 in response to epidermal growth factor. Mol Biol Cell 2006; 17: 2267–2277.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Marshall AJ, Niiro H, Yun TJ, Clark EA . Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway. Immunol Rev 2000; 176: 30–46.

    Article  CAS  PubMed  Google Scholar 

  22. Kerbauy DB, Deeg HJ . Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome. Exp Hematol 2007; 35: 1739–1746.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Wilber A, Nienhuis AW, Persons DA . Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood 2011; 117: 3945–3953.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189–199.

    Article  CAS  PubMed  Google Scholar 

  25. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  PubMed  Google Scholar 

  26. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088.

    CAS  PubMed  Google Scholar 

  27. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425.

    Article  CAS  PubMed  Google Scholar 

  28. di Giacomo V, Matteucci A, Stellacci E, Battistini A, Di Baldassarre A, Capitani S et al. Expression of signal transduction proteins during the differentiation of primary human erythroblasts. J Cell Physiol 2005; 202: 831–838.

    Article  CAS  PubMed  Google Scholar 

  29. Missiroli S, Etro D, Buontempo F, Ye K, Capitani S, Neri LM . Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells. Int J Biochem Cell Biol 2009; 41: 570–577.

    Article  CAS  PubMed  Google Scholar 

  30. Faenza I, Matteucci A, Bavelloni A, Marmiroli S, Martelli AM, Gilmour RS et al. Nuclear PLCbeta(1) acts as a negative regulator of p45/NF-E2 expression levels in Friend erythroleukemia cells. Biochim Biophys Acta 2002; 1589: 305–310.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Italian MIUR-FIRB and the Italian Society of Experimental Hematology (SIES).

Author information

Authors and Affiliations

  1. Department of Human Anatomical Sciences, Cellular Signalling Laboratory, University of Bologna, Bologna, Italy

    M Y Follo, S Mongiorgi, A M Martelli, G Fioravanti, L Manzoli & L Cocco

  2. Department of Hematology and Medical Oncology ‘L. e A. Seràgnoli’, University of Bologna, Bologna, Italy

    C Clissa, S Paolini, G Martinelli & C Finelli

  3. Istituto per i Trapianti d'Organo e l'Immunocitologia del C.N.R., Sezione di Bologna c/o I.O.R., Bologna, Italy

    A M Martelli

Authors
  1. M Y Follo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Mongiorgi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Clissa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Paolini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G Martinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A M Martelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Fioravanti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L Manzoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Finelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L Cocco
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Cocco.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Follo, M., Mongiorgi, S., Clissa, C. et al. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients. Leukemia 26, 2474–2482 (2012). https://doi.org/10.1038/leu.2012.133

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2012.133

Keywords

This article is cited by

Search

Advanced search

Quick links